Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Enumeral Biomedical Holdings, Inc.s101673_ex99-1.htm

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 12, 2015

 

Enumeral Biomedical Holdings, Inc.

 

(Exact name of registrant as specified in its charter)

 

Delaware 000-55415 99-0376434
(State or Other Jurisdiction (Commission File (I.R.S. Employer
of Incorporation) Number) Identification Number)

 

200 CambridgePark Drive, Suite 2000  
Cambridge, Massachusetts 02140
(Address of Principal Executive Offices) (Zip Code)

  

(617) 945-9146 

(Registrant’s telephone number, including area code)

 

N/A 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 
 

 

Item 2.02 Results of Operations and Financial Condition.

  

On August 12, 2015, Enumeral Biomedical Holdings, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2015. The press release is attached to this report as Exhibit 99.1.

  

The information in this Form 8-K and Exhibit 99.1 is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor is it deemed incorporated by reference in any filing under the Securities Act of 1933 or Securities Exchange Act of 1934, except as specifically indicated in any such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)                       Exhibits

 

Exhibit
No.
  Description
     
99.1   Press Release dated August 12, 2015.

 

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

           
    ENUMERAL BIOMEDICAL HOLDINGS, INC.  
       
Dated: August 12, 2015   By: /s/ Kevin G. Sarney  
      Name: Kevin G. Sarney  
    Title: Vice President of Finance, Chief  
        Accounting Officer and Treasurer  

 

 
 

 

EXHIBIT INDEX

 

Exhibit
No.
  Description
     
99.1   Press Release dated August 12, 2015.